Evidence map›Paper›PMID 34264513›Full record

ReviewPharmacological reports : PR2021

Cannabinoids and their derivatives in struggle against melanoma.

Paweł Marzęda, Małgorzata Drozd, Paula Wróblewska-Łuczka, Jarogniew J Łuszczki

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmacological reports : PR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paweł MarzędaDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090, Lublin, Poland.ORCID http://orcid.org/0000-0003-1697-5497
Małgorzata DrozdDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090, Lublin, Poland.ORCID http://orcid.org/0000-0002-0710-2451
Paula Wróblewska-ŁuczkaDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090, Lublin, Poland.ORCID http://orcid.org/0000-0002-7099-1968
Jarogniew J ŁuszczkiDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090, Lublin, Poland. jluszczki@yahoo.com.ORCID http://orcid.org/0000-0002-3059-0393
Medical University of Lublin · PL

Funding

Uniwersytet Medyczny w Lublinie DS 474/2020
6 · The paper itself

Abstract

Melanoma is one of the most aggressive malignances in human. Recently developed therapies improved overall survival rate, however, the treatment of melanoma still remains a challenging issue. This review attempts to summarize recent advances in studies on cannabinoids used in the setting of melanoma treatment. Searches were carried out in PubMed, Google Scholar, Scopus, Research Gate. Conclusions after analysis of available data suggest that cannabinoids limit number of metastasis, and reduce growth of melanoma. The findings indicate that cannabinoids induce apoptosis, necrosis, autophagy, cell cycle arrest and exert significant interactions with tumor microenvironment. Cannabinoids should be rather considered as a part of multi-targeted anti-tumor therapy instead of being standalone agent. Moreover, cannabinoids are likely to improve quality of life in patients with cancer, due to different supportive effects, like analgesia and/or anti-emetic effects. In this review, it was pointed out that cannabinoids may be potentially useful in the melanoma therapy. Nevertheless, due to limited amount of data, great variety of cannabinoids available and lack of clinical trials, further studies are required to determine an exact role of cannabinoids in the treatment of melanoma.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisAutophagyCannabinoidsHumansMelanomaQuality of LifeSkin NeoplasmsTumor MicroenvironmentAntineoplastic Agents, PhytogenicCannabinoidsAntitumor effectCannabinoidsCB1 receptorCB2 receptorMelanoma

Identifiers

PMID34264513
PMCPMC8599338
OpenAlexW3180160934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.